Objective: Vascular calcifications (VCs) may be a prognostic factor for outcome after endovascular treatment of peripheral arterial disease (PAD). Semi-quantitative analysis with X-ray imaging is the main limiting factor for assessing VCs. The aim of the present study was to find a correlation between the amount of VC with a CT scan quantification and mid-term results of endovascular treatment of TASC C/D femoropopliteal (FP) lesions.
Introduction
The most common cause of peripheral arterial disease is atherosclerosis. Despite being exposed to similar risk factors, peripheral arteries develop heterogeneous atherosclerotic lesions. Our previous work showed that carotid arteries develop predominantly lipid-rich lesions and microcalcifications, while femoral arteries develop fibrotic lesions, with extensive vascular calcification (VC) and frequent presence of osteoid tissue (1) (2) (3) (4) . These differences may have major clinical implications. Firstly, VC may destabilise atheromatous plaques and contribute to plaque rupture (5-7). Moreover, advanced and extensive VC contributes to arterial stiffness and hypertension, an important risk factor for plaque rupture (8, 9) .
Secondly, the presence of VC may influence the technical success rate and outcomes of peripheral endovascular procedures (10). It is noteworthy that severe VC is often considered an exclusion criterion in femoropopliteal clinical study protocols. Moreover, balloon angioplasty of severe calcified lesions is limited by early elastic recoil and poor acute and long-term outcomes (11) . Although nitinol stents are designed to prevent elastic recoil and constrictive remodelling, severe VC may prevent stent expansion, resulting in poorer outcomes when compared to fully expanded stents (12) . Also, it seems that VC may influence the efficacy of drug-eluting balloons during revascularisation of femoropopliteal lesions, mainly in cases of circumferential distribution (13) .
Nevertheless, few data are available to determine the influence of VC on femoropopliteal endovascular treatment outcomes. In the present study, we sought to determine the perioperative and mid-term outcomes following long femoropopliteal stenting according to preoperative VC burden.
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Patients and Methods
Population
Patients included in this study belong to two published prospective registries (14, 15) Protocols were approved by local ethics committees and all patients gave their informed consent.
CTA analysis and quantification of VC
All computed tomography angiograms (CTAs) were analysed with a dedicated workstation (17) (18) (19) (20) (EndoSize®, Therenva, France) by one investigator blinded to outcomes. Centrelines from the common femoral artery to the end of the popliteal artery (Fig. 1A) were manually extracted for femoropopliteal occlusions, otherwise automatic extraction was used (in case of stenosis). A region of interest (ROI) was determined as a cylinder centred around centrelines (Fig. 1B) whose diameter was manually adjusted to ensure all VC was included. Within the ROI, a dedicated program allowed segmentation of both arterial lumen (ALu) and VC ( Fig. 1C-D) with a thresholding tool. The difference between ALu and VC was based on HU density (21) (22) (23) : voxels in the range 400-3000 HU were considered VC (and quantified in mm 3 ) whereas voxels in the range 100-400 HU were considered ALu (Fig. 1C-D) . Volume of M A N U S C R I P T
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VC and ALu were calculated for the entire femoropopliteal artery but also at the level of the treated segment. The percentage of VC and ALu at the level of the treated segment was determined by the ratio between the volume of VC and ALu and the volume of the ROI. The other CTA parameters analysed were the length of lesions and the diameter of the healthy superficial femoral artery.
Definition of groups
In order to compare pre-, peri-and post-operative data according to the amount of VC, 3
groups were established. The overall population was divided according to the rate of VC, from the lowest to the highest percentage of VC: group 1 (G1) included the 1st quartile of VC, G2 included the 2nd and 3rd quartiles and G3 included the 4th quartile.
Follow-up
Follow-up consisted of a clinical examination, measurement of ankle-brachial index (ABI) and a duplex scan at 1, 3, 6, 9, 12, 18 months then annually thereafter. An X-ray of the thighs with two separate incidences of at least 45° was taken after 12 months in order to test for stent fracture. All of the data were entered in a prospective follow-up register.
Endpoints
The primary endpoint compared between groups was in-stent thrombosis during follow-up.
Secondary endpoints were target lesion revascularisation (TLR), target extremity revascularisation (TER) and in-stent restenosis (ISR). Endpoint definitions have already been described in articles reporting on the respective results recorded for both cohorts, and comply with international definitions.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Statistical analysis
Continuous variables were presented as mean ± SD and categorical variables as count and percentages. Pearson's chi-square test was used for comparisons of continuous variables, and one-way factorial ANOVA for categorical data after testing the normality of the data, and then differences among means were analysed using post-hoc 
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Results
Demographic data
Of the 103 patients of both registries, only those with preoperative computed tomography angiography (CTA) were included. Patients with only a duplex scan (n=29), magnetic resonance angiography (n=25) or without a CTA (n=10) were excluded from the study.
Thirty-nine patients were therefore included for analysis. Every patient in group 1 had a VC rate in the lesion area of <1%; this group was therefore considered the non-calcified group (n=10). Patients in group 3 had a VC rate >20%; this group was considered the heavily calcified group (n=10). Group 2 consisted of patients with a VC rate in the range 1-20% and was considered as the intermediate calcification group (n=19).
As shown in Table 1 , there was no difference in demographic characteristics between groups, except a significantly higher rate of hyperlipidaemia in group 3 (p=0.008). Statin therapy rates
were not different.
Lesions and intraoperative data (Table 2)
With regard to anatomical characteristics of the femoropopliteal segment, it was noted that the diameter was different between groups with the ANOVA test, and post-hoc tests revealed that this difference was significant between group 1 and 3 (p<0.0001) and between group 2 and 3 (p=0.0002). There was no difference between group 1 and 2 (p=0.217). A significant correlation was found between femoropopliteal segment diameter and the amount of VC (Fig. 2) . Given the fact that groups were determined according to VC rate, a significant difference was found between them for Ca and ALu volume in the lesion area and for the overall femoropopliteal segment. With regard to endovascular treatment, no difference was observed for characteristics of implanted stents nor for use of X-ray and contrast load.
Perioperative results
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During follow-up, 10 (25.6%) stent thromboses occurred ( When the date of occurrence of stent thrombosis was analysed (Fig. 3) , a trend was shown:
heavy Ca was associated with early stent thrombosis, while no Ca was associated with late stent thrombosis. More precisely, heavy Ca presented a stent thrombosis at 1 month while every patient with no Ca presented a stent thrombosis between the 6th and the 24th months.
All patients with intermediate Ca presented a stent thrombosis after the 48th month. Rates of in-stent restenosis, TLR and TER are provided in Table 3 and were not statistically different between groups.
Risk factor for in-stent thrombosis
Results of the univariate/multivariate analysis are provided in Tables 4 and 5 . On univariate analysis, the femoropopliteal diameter was higher in the in-stent thrombosis population (6.1±
1.3 mm vs. 5.2 ± 1.1, p=0.05) but on multivariate analysis it did not appear to be significant, although a trend towards a protective effect of the femoropopliteal diameter on in-stent thrombosis was noted ( 
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Discussion
In this study, we report that the rate of VC has a high impact on endovascular treatment outcomes after long femoropopliteal stenting. Given that a high amount of VC is frequently an exclusion criterion, few data are available concerning results of endovascular therapies in calcified arteries because it is assumed that outcomes are poor with this specific arterial feature. In this paper, we sought to determine the role of VC after stent implantation. It seems that, as assumed, a high rate of VC is at risk of technical failure and poor outcomes but also arteries with no calcification. An intermediate rate of VCs may protect against in-stent thrombosis.
Classification
Currently, neither quantitative nor qualitative preoperative VC assessment is available in routine practice. Indeed, current VC quantitative grading is based on subjective, semiquantitative, angiographic-and fluoroscopic-based assessments. Furthermore, VC nature and composition cannot be determined by current non-invasive methods. Among non-invasive preoperative imaging methods, CTAs are still more available and cheaper than magnetic resonance angiographies and are widely used in current practice. Two previously published grading systems are often used in studies to assess VC but the quantification is based on angiographic images and remains subjective (24, 25) . In 2014, Rocha-Singh et al. (25) proposed a peripheral arterial calcium scoring system (PACSS) and a method for its clinical validation. In this classification, the scoring system takes into account the pathological location of calcification (intima, media, combined) along with the location and length of the has been reported to assess VC and stent expansion. In this particular study, a high rate of VC was found to be a factor for stent underexpansion (26 
Lesions and intraoperative data
With regard to lesions and intraoperative data, we observed that VCs were associated with a larger femoropopliteal diameter. Enlargement of femoropopliteal arteries was probably linked to positive vessel remodelling. Indeed, during the atherosclerotic process, femoral arteries may locally develop compensatory enlargement to compensate for lumen narrowing by plaque formation (29) . Consequently, we can assume that positive femoropopliteal remodelling could be associated with a greater amount of VCs.
Severe VC is associated with perioperative in-stent thrombosis
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Occurrence of in-stent thrombosis at 1 month is significantly higher in most calcified groups. 
Mid-term in-stent thrombosis and restenosis with soft plaques
The multivariate analysis concluded that patients with intermediate VCs are less likely to present an in-stent thrombosis during follow-up in comparison to others. Indeed, patients with severe VC presented in-stent thrombosis during the perioperative period and patients with soft plaques were at risk of in-stent thrombosis at mid-term. Analysis of in-stent thrombosis timing suggests that the in-stent thrombosis mechanism may be different. Technical failure, as described above, may be the main cause of perioperative in-stent thrombosis. However, for a longer follow-up, a biological factor may explain in-stent thrombosis. Therefore, this observation may suggest that lesions with a low amount of VC are an entity at risk of complications following endovascular revascularisation. This hypothesis derives from fundamental research where it was recently found that osteoprotegerin (OPG) and osteoid metaplasia (OM) were associated with carotid plaque stability (1) . In this study, a significantly higher presence of OM, OPG and pericytes was noted in asymptomatic compared to symptomatic plaques. Without femoropopliteal plaque analysis, these results cannot be transposed and a plaque accident is not similar to a stent thrombosis but it can be M A N U S C R I P T
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assumed that femoropopliteal VC could have the same behaviour on the stented plaque as the carotid plaque. An interesting study on coronary arteries failed to show that severely calcified arteries have a lower rate of in-stent restenosis whereas the working assumption was based on previous histological findings (32) . The authors noted that restenosis is composed of neointimal hyperplasia derived from smooth muscle cells and fibroblasts migrating from the vessel wall. Since normal components of calcific arterial walls are largely replaced by calcium deposits and fibrosis, the authors suggested that stented calcific arteries would restenose less than non-calcified arteries. Finally, despite the potential role played by calcifications, it has been shown also in coronary artery disease that a pathophysiological process characterized by impaired endothelial coverage, persistent fibrin deposition, and ongoing vessel wall inflammation contribute to late in stent thrombosis (33) .
Limitations
The main limitation of this study is obviously the number of patients enrolled. Although statistical tests designed for small samples were used, a greater number of patients would probably have highlighted other differences between the groups. For that reason, the results of the multivariate analysis should be interpreted with caution. It is probably more appropriate to conclude that we found a trend more than there is clearly a significant difference between groups. Moreover, the rate of stent thrombosis is especially high in this study but does not reflect the rate found in both registries. As a reminder, the rate if in-stent thrombosis at one year was 11.3% and 14.6% in STELLA and STELLA PTX registries respectively. But in the paper of Bosier et al (34) , this rate was 24% at one year, almost similar to our study (25.6%).
Grouping of both registries may also be interpreted as a bias because bare metal stent (BMS) and drug-eluting stent (DES) outcomes have been mixed. However, it can be observed that the DES rate was similar in all groups and recently, we have shown with a propensity score-M A N U S C R I P T
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matched analysis that, according to both registries, paclitaxel-eluting stents do not seem to provide benefits in terms of clinical and morphological outcomes for TASC C/D lesions compared to bare metal stent (35) . Moreover, there is an heterogeneity in the dual antiplatelet therapy (DAPT) prescription in the present cohort and even though there is no high level of evidence for DAPT after peripheral endovascular stenting, coronary studies recommended DAPT systematically for a minimum duration of 6 months to prevent in stent thrombosis (36) .
Our working hypothesis needed to focus on two different lesions in terms of plaque composition: these were no VC and severe VC. The rate of VC according to median values ultimately showed that group composition was appropriate to our objective to compare essentially no Ca and severe Ca. The intermediate VC group including the 2nd and 3rd
quartiles of the entire population corresponds to the "moderate" group in many studies using a 3-grade VC classification. We do not support that four grades of VC classification would be relevant since our hypothesis was that no and severe VC groups are of interest and leads to different outcomes with different mechanisms.
Conclusion
This study showed that an accurate quantification of VC is interesting to assess endovascular outcomes after stenting of FP lesions. It seems that both absence and heavily calcifications are at risk of in-stent thrombosis. Calcification of a certain quantity and quality may be necessary for plaque stability. Additional data with a larger population are mandatory to confirm these results.
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